YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
YARDLEY, Pa., August 20, 2026--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On August 17, 202…
Savara SVRA continues to advance Molbreevi (molgramostim inhalation solution), its lead and only late-stage pipeline candidate, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare, chronic lung disease with no FDA…
Palvella Therapeutics Inc. Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare di…
On June 22, 2026, David Lowrance, the Chief Financial Officer of Savara (NASDAQ:SVRA), executed the exercise of 580,187 options on Common Stock followed by the sale of 394,528 shares in the open market, as reported in this SEC Form 4 filin…
[Financial market sector Healthcare on blue finance background from graphs, charts. 3D render] Vladimir Zakharov A screen of U.S. healthcare stocks with market capitalizations between $300M and $2B highlights several small-cap companies, i…
Superstring Capital Management cut its stake in UroGen Pharma Ltd. (NASDAQ:URGN), selling 330,983 shares in the first quarter in an estimated $6.64 million trade based on average quarterly pricing, according to a May 14, 2026, SEC filing.…
Key Points Superstring Capital sold 330,983 shares of UroGen Pharma Ltd last quarter; the estimated transaction value was $6.64 million based on quarterly average pricing. The quarter-end position value decreased by $9.86 million, reflecti…
Superstring Capital Management disclosed a new position in Vir Biotechnology(NASDAQ:VIR), acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing. What happened Ac…
Key Points Superstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices. The quarter-end position value rose $6.55 million, reflecting the new s…
Savara Inc. (NASDAQ:SVRA) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 12, 2026, Savara Inc. (NASDAQ:SVRA) reported Q1 EPS of (15c), versus the consensus estimate of (14c). Chair and CEO Matt Pauls said the company ended…
LANGHORNE, Pa., May 11, 2026--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participat…
The United States market remained flat over the last week, yet it has experienced a 30% rise over the past 12 months with earnings forecasted to grow by 16% annually. In this context of robust growth potential, identifying high-growth tech…
The United States market remained flat over the last week but has risen 16% over the past year, with earnings projected to grow by 16% annually in the coming years. In light of these conditions, identifying high growth tech stocks involves…
According to a filing with the Securities and Exchange Commission dated Feb. 17, VR Adviser, LLC increased its position in Savara(NASDAQ:SVRA) by 1,059,332 shares during the fourth quarter. The fund’s Savara stake ended the quarter valued…
[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers * The U.S. FDA will review Savara's (SVRA [https://seekingalpha.com/symbol/SVRA]) resubmitted BLA for Molbreevi (molgramostim inhalation solution) to treat the rare lung…
LANGHORNE, Pa., February 13, 2026--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On February…
As the U.S. stock market kicked off February with significant gains, highlighted by the Dow Jones Industrial Average's 515-point surge and the S&P 500 nearing a record high, investors are keenly observing how these developments impact high…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Why the Savara loan amendment matters for Hercules Capital Hercules…
-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI -- LANGHORNE, Pa., January 27, 2026--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the C…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Savara between March 7, 2024 and…
As the U.S. market continues to reach new highs, with the S&P 500 and Dow Jones Industrial Average setting records despite concerns over a DOJ probe into Fed Chair Powell, investors are keeping a keen eye on high-growth tech stocks that co…
(RTTNews) - Savara Inc. (SVRA) announced that it has resubmitted the Biologics License Application to the FDA for MOLBREEVI, its investigational therapy currently in Phase 3 development, seeking approval for the treatment of autoimmune pul…
* Savara ( [https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54382048&newsitemid=20251221214643&lan=en-US&anchor=Savara+Inc.&index=1&md5=f6d458de2e8896cb40f3e1dfe1f261c2]SVRA [https://seekingalph…
As the U.S. market grapples with fluctuating indices and AI bubble concerns, the Dow Jones Industrial Average recently hit an all-time high before retreating, while tech-heavy stocks like those in the Nasdaq face pressure amid broader econ…
[Scientist looking through a microscope] sanjeri/E+ via Getty Images * Savara Inc. (SVRA [https://seekingalpha.com/symbol/SVRA]) pared a loss and ticked higher by 0.2% amid takeover speculation. * There's speculation that Savara may have a…
We recently published 10 Small Caps With Big Double-Digit Gains. Savara Inc. (NASDAQ:SVRA) is one of the top performers of last week. Savara soared by 27.84 percent week-on-week, as investors positioned their portfolios ahead of business u…
The U.S. stock market recently experienced a significant downturn, with major indices such as the Nasdaq and S&P 500 closing sharply lower, driven by a notable decline in technology shares. In this environment of heightened volatility and…
LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) for violations of…
LOS ANGELES, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act…
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses…
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Savara Inc. (“Savara” or “the C…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Savara between March 7, 202…
LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) for violations of…
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Per…
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact th…
LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Savara, Inc., (“Savara” or the "Company") (NASDAQ: SVRA) investors off a class action on behalf of investors that bought securities between March 7, 2024 and May 2…